Jump to content

EGIS-7625

From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by Ffffrr (talk | contribs) at 01:07, 14 September 2022 (Importing Wikidata short description: "Chemical compound"). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
EGIS-7625
Clinical data
ATC code
  • none
Legal status
Legal status
  • UN: Unscheduled
Identifiers
  • 5-(4-Benzylpiperazin-1-yl)-2-methyl-4-nitroaniline
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H22N4O2
Molar mass326.400 g·mol−1
3D model (JSmol)
  • CC1=CC(=C(C=C1N)N2CCN(CC2)CC3=CC=CC=C3)[N+](=O)[O-]
  • InChI=1S/C18H22N4O2/c1-14-11-18(22(23)24)17(12-16(14)19)21-9-7-20(8-10-21)13-15-5-3-2-4-6-15/h2-6,11-12H,7-10,13,19H2,1H3
  • Key:ZEFXWOMFCPRXJW-UHFFFAOYSA-N

EGIS-7625 is a selective and competitive 5-HT2B receptor antagonist. It is experimentally proven to be directly associated with smooth stomach muscle constriction of white rats in vivo, and variably effective in provoking a similar response in in vitro human stomach cells. In high blood concentrations, it causes mild constriction of rabbit pulmonary arteries.[1]

References

[edit]
  1. ^ Kovács A, Gacsályi I, Wellmann J, Schmidt E, Szücs Z, Dubreuil V, et al. (2003). "Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonist". Cardiovascular Drugs and Therapy. 17 (5–6): 427–34. doi:10.1023/B:CARD.0000015857.96371.43. PMID 15107597. S2CID 11532969.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=EGIS-7625&oldid=1110171449"